Victoza® label in the US updated to include data showing superior efficacy when compared to Januvia®
2012-04-06 · Novo Nordisk A/S · original novonordisk.com ↗
Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for Victoza® (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to Januvia® (sitagliptin). Further information: Media: Investors: Mike Rulis Klaus Bülow Davidsen Tel: (+45) 3079 3573 Tel: (+45) 4442 3176 [email protected] [email protected] Frank Daniel Mersebach Tel: (+45) 4442 0604 [email protected] Lars Borup Jacobsen Tel: (+45) 3075 3479 [email protected] In North America: Ambre Morley Jannick Lindegaard Tel: (+1) 609 216-5240 Tel: (+1) 609 786 4575 [email protected] [email protected] Company Announcement no 22 / 2012
The release as fetched from its publisher. novonordisk.com ↗